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AAV-mediated in vivo functional selection
of tissue-protective factors against ischaemia
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Functional screening of expression libraries in vivo would offer the possibility of identifying
novel biotherapeutics without a priori knowledge of their biochemical function. Here we
describe a procedure for the functional selection of tissue-protective factors based on the
in vivo delivery of arrayed cDNA libraries from the mouse secretome using adeno-associated
virus (AAV) vectors. Application of this technique, which we call FunSel, in the context of
acute ischaemia, revealed that the peptide ghrelin protects skeletal muscle and heart from
ischaemic damage. When delivered to the heart using an AAV9 vector, ghrelin markedly
reduces infarct size and preserves cardiac function over time. This protective activity
associates with the capacity of ghrelin to sustain autophagy and remove dysfunctional
mitochondria after myocardial infarction. Our findings describe an innovative tool to identify
biological therapeutics and reveal a novel role of ghrelin as an inducer of myoprotective
autophagy.
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S
ince the birth of genetic engineering, the screening of
genetic libraries has provided a powerful means for the
identification of genes, proteins and small nucleic acids
possessing desirable characteristics. Initial screenings, based on
nucleic acid hybridization or antibody reactivity in cell culture-
based assays, were later complemented by functional screenings,
relying on selection for survival, transformation or modulation
of cell function. Although these cell-based approaches have
generated essential biological information with important upshots
on drug target identification, they suffer a major, unavoidable
limitation, namely, they cannot predict the in vivo relevance of
the selected molecules. In addition, several factors exert beneficial
function in vivo by multiple, pleiotropic mechanisms, the
individual relevance of which cannot be anticipated by in vitro
assays. Thus, in only a very few cases, the factors that emerged
from these in vitro screenings have advanced to clinical use.
In contrast, the possibility of screening libraries for a given
function directly in vivo would allow for the direct identification
of factors with proven functional relevance.
Here, we report on the development of an in vivo, functional
selection procedure (FunSel) for the identification of factors
protecting against tissue degeneration, and we provide proof-of-
principle application of this procedure to identify therapeutic
factors for acute myocardial infarction (MI) and limb ischaemia.
We generated an arrayed library of cDNAs encoding murine-
secreted factors in vectors based on the adeno-associated virus
(AAV); then, we submitted this library to iterative cycles of
selection in the ischaemic skeletal muscle to identify factors with
myoprotective function; finally, we tested and characterized the
effect of the selected molecule in models of peripheral and cardiac
ischaemia. FunSel exploits three unique properties of AAV
vectors, namely their exquisite in vivo tropism for post-mitotic
cells (including cardiomyocytes and skeletal muscle fibres1,2),
their prolonged transgene expression and the possibility to
produce high titre vector preparations, often in excess of 1 1014
viral particles per ml (recently reviewed in ref. 3).
Under our experimental conditions, FunSel led to the selection
of ghrelin, a 28-amino-acid peptide hormone, which is normally
produced by the stomach and octanoylated on serine 3 by the
ghrelin-O-acyltransferase (GOAT) enzyme4,5 to generate acyl
ghrelin. This modified peptide binds the growth hormone
secretagogue receptor-1a (GHSR-1a) to induce growth hormone
release and perform multiple endocrine functions6,7. The major
form of circulating ghrelin, however, is not acylated (des-acyl
ghrelin) and acts through a still unidentified receptor, different
from GHSR-1a8–10. The mechanism by which des-acyl ghrelin
exerts its functions in various tissues still remains largely
unknown.
Autophagy has progressively gained remarkable attention over
the last few years as an adaptive response against stress, capable to
protect various tissues from injury and maintain tissue home-
ostasis by the removal of dysfunctional organelles through the
lysosomal degradative pathway11–16. In the heart, converging
evidence has indicated that autophagy exerts beneficial effects17.
During heart failure, this process protects against progressive
cardiac dysfunction17; ischaemia itself stimulates autophagy as an
adaptive mechanism18. Consistent with this protective role,
defects in cardiomyocyte autophagy induce cardiac dysfunction
in both animal models19 and patients with inherited defects of
proteins involved in the autophagic process20.
We report here that des-acyl ghrelin, once expressed in the
heart after MI and independent from its endocrine function,
remarkably, protects cardiac cells from ischaemic damage and
sustains cardiac function over time, whereas, in the skeletal
muscle, it promotes muscle fibre regeneration after ischaemia.
These effects parallel the previously uncovered property of
unmodified ghrelin to directly induce cardiomyocyte and skeletal
muscle fibre autophagy, resulting in the removal of dysfunctional
mitochondria.
Results
In vivo functional selection of tissue protective factors. FunSel
is based on iterative cycles of in vivo transduction of an AAV
vector library coding for different transgenes, followed by the
induction of a selective stimulus (Fig. 1a). A library of AAV
plasmids, each one coding for a specific factor, is used for the
batch production of AAV vectors, which are then injected in vivo
to transduce permissive cells (for example, myofibers, cardio-
myocytes, photoreceptors, pancreas b-cells); in principle, each
vector transduces a different cell. After a few weeks, a selective
stimulus is applied (for example, ischaemia for skeletal muscle or
heart, retinal degeneration or chemical induction of cell death).
Then, vector cDNA inserts are recovered from the injected tissue
and used to generate a new AAV preparation, which is used for
another cycle of selection. Should any of the viral transgenes exert
a protective or regenerative effect on the cell expressing it (shown
in red in Fig. 1a), it becomes progressively enriched along the
iterative cycles of selection.
Theoretical considerations were elaborated to support the
feasibility of FunSel. The ultimate purpose of the procedure is the
in vivo selection of a specific AAV vector, coding for a desired
transgene (T) from a pool of several AAVs (A), each one coding
for a different factor. The ratio between T and A (herein defined
as R¼T A 1 (equation 1)) indicates the success of the selection
procedure. At least six parameters influence AAV vector-
mediated selection: (i) the initial number of different vectors
included in the original pool (POOL), (ii) the efficiency of
transduction (ET), (iii) the number of different vectors entering
each cell (multiplicity of infection, MOI), (iv) the efficiency of
selection (ES, measuring the selective advantage offered by the
transgene), (v) the effect of a selected transgene on neighbouring,
non-transduced cells (COSEL) and (vi) the number of iterative
selection cycles (CYCLE; Supplementary Table 1). At each cycle
of selection, when the number of vectors with the desired
transgene is set to 1 (T¼ 1), the total number of AAV vectors (A)
after transduction and selection consists of the sum of: (i) the
number of vectors co-infecting the same cell as the desired vector
(MOI); plus (ii) the number of vectors present in the cell close to
the selected cells and co-selected with this (COSEL ETMOI);
plus (iii) the total number of vectors in the cells containing
other transgenes but surviving the selection ((POOLMOI)
COSELETMOI) (1 ES). Thus, at the end of the FunSel
procedure, R becomes as shown in Fig. 1b, to be compared with
its value at start, when R¼ 1 POOL 1 (equation 2).
Figure 1c shows how varying MOI and COSEL affect selection
efficiency. In all of the cases considered, robust transgene
selection (over tenfold) is achieved with a relatively small number
of selection cycles (from 1 to 5). These mathematical considera-
tions support the feasibility of FunSel over a variegated range of
experimental settings.
Virologic feasibility of FunSel. We generated a collection of 100
sequence-verified, AAV vectors coding for secreted proteins,
as identified in the FANTOM3 project21. These genes were
representative of various categories, including cytokines and
interleukins (11 clones), hormones and growth factors (25),
extracellular matrix proteins (11), secreted enzymes (18), other
proteins of miscellaneous function (22) and proteins of unknown
function (13; cf. complete list in Supplementary Table 2). The
cDNA of all these factors was cloned into an AAV vector plasmid
under the control of the CMV IE promoter.
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To explore the efficiency of simultaneous packaging of multiple
AAV vector plasmids, we obtained AAV2 pools with complexities
of 25, 50 and 100 different vectors (Supplementary Table 2). By
analysing the frequency of ten randomly chosen inserts in the
three preparations, we found that cDNA inserts of up to 1,500 bp
were packaged at an efficiency within ±2-fold compared with
those expected, and those with a longer size, with an efficiency
within ±3-fold, irrespective of pool complexity (Supplementary
Fig. 1a). Both intervals appeared acceptable for the purpose of
FunSel.
To verify the infectivity of individual AAV vectors within their
pools, we transduced skeletal muscles with the AAV2 pools
composed of either 25 or 100 clones; in both cases, the relative
abundance of each of the individual constructs at 3 weeks after
transduction was in the ±2-fold range compared with the
value expected according their dilution in the infecting pool
(Supplementary Fig. 1b). Finally, we ascertained the expression of
the transduced clones in vivo. The same number of viral particles
of the AAV2 pools composed of 25, 50 or 100 vectors, as well as
two individual AAV2 vectors coding for two specific clones in the
pools (clones E2 and C12), were injected into the skeletal muscle.
After 3 weeks in all cases, the relative abundance of E2 and C12
mRNAs corresponded to the dilution of the encoding vectors in
the original mixture (Supplementary Fig. 1c,d). Vector pool
complexities of 25 and 50 allowed relatively robust expression of
the investigated transgenes.
Functional selection of ghrelin after hindlimb ischaemia. We
wanted to obtain a proof-of-principle of FunSel in identifying
factors protecting against acute ischaemia. We bilaterally injected
a pool of 30 different AAV2 vectors (coding for the factors listed
AAV plasmid library
Pooled production
of AAV vectors
Injection in vivo to
transduce permissive
tissues
Iteration of selection
(several cycles)
Induction of
selective stimulus
Recovery of viral
genomes and
re-cloning into AAV
vector plasmids
Mouse 1.1
Ischaemia: + – + – + – + – + – + –
AAV
pool
2 kb
1.5 kb
1 kb
0.75 kb
Cycle 1
cD
N
A 
in
se
rts
Cycle 2 Cycle 3 Cycle 1
0
0.05
0.10
0.15
0.20
G
hr
el
in
 A
AV
/to
ta
l A
AV
0.25
Cycle 2 Cycle 3
*** Ischemia
No ischemia
*
Mouse 1.2 Mouse 2.1 Mouse 2.2 Mouse 3.1 Mouse 3.2
Pooled AAV vector
production 0.50 MOI: 1
ET: 0.3
ES: 0.5
COSEL: 0
POOL: 50
Cycle: 1–5
MOI: 10
ET: 0.3
ES: 0.5
COSEL: 0
POOL: 50
Cycle: 1–5
MOI: 3
ET: 0.3
ES: 0.5
COSEL: 3
POOL: 50
Cycle: 1–5
ET: 0.3
ES: 0.5
MOI: 1
COSEL: 10
POOL: 50
Cycle: 1–5
0.40
0.30
0.20
0.10
0
1
N. cycles N. cycles
2 3 4 5 1 2 3 4 5
1 2 3 4 51 2 3 4 5
Tr
a
n
sg
en
e 
AA
V/
to
ta
l
AA
V 
(R
)
0.50
0.40
0.30
0.20
0.10
0
Tr
a
n
sg
en
e 
AA
V/
to
ta
l
AA
V 
(R
)
0.50
0.40
0.30
0.20
0.10
0
Tr
a
n
sg
en
e 
AA
V/
to
ta
l
AA
V 
(R
)
0.50
0.40
0.30
0.20
0.10
0
Tr
a
n
sg
en
e 
AA
V/
to
ta
l
AA
V 
(R
)
R =
AAVSEL 1
+ +
AAVINPUT N. vectors
co-infecting the same
cell as the selectable
transgene
N. vectors in cells
co-selected due to a
bystander effect of the
selectable transgene
N. vectors in cells not
containing the selectable
transgene but surviving the
selection
MOI COSEL×ET×MOI ((PooL-MOI)-COSEL×ET×MOI)×(1–ES)
Few weeks
Few weeks
=
Figure 1 | Identification of ghrelin as a myoprotective factor by the application of FunSel. (a) Outline of the FunSel procedure. Red: selected gene.
(b) Formula defining the efficiency of transgene selection (R) according to the variables affecting FunSel (Supplementary Table 1). (c) FunSel simulation.
In an ideal situation, the number of transduced cells is set at 30% (ET¼0.3, as it is common for muscle and cardiac AAV transduction3), each vector
enters one cell (MOI¼ 1), there is no bystander effect (COSEL¼0), and 50% of cells with the transgene are selected (ES¼0.5). The upper left panel
shows the effect of performing five iterative cycles of selection under these conditions with a pool of 50 vectors (POOL¼ 50). The frequency of a selected
vector, starting from 0.02 (1 50 1) before the selection, doubles after one cycle and reaches 0.14 and 0.40 after 3 and 5 cycles, respectively. Increasing the
MOI or COSEL effect decrease efficiency of selection, as shown in the lower left (MOI¼ 10) and upper right (COSEL¼ 10) panels, respectively. Under these
conditions, three cycles of selection enrich the desired transgene 2.3- or 5-folds, respectively. In a realistic scenario, transduction occurs with 50 vectors
(POOL¼ 50) at an efficiency of 30% (ET¼0.3), three vectors per cell (MOI¼ 3), two selected cells in addition to the transduced one (COSEL¼ 3)
and ES¼0.5. Under these conditions, enrichment for the transgene becomes 2-fold after one cycle, 4.5-fold after three cycles and 7-fold after five cycles
(lower right panel). (d) Iterative enrichment for the ghrelin cDNA after three cycles of selection in ischaemic skeletal muscles. The pictures shows PCR
fragments corresponding to the cDNA inserts, generated with primers flanking the AAV inserts. The first ladder corresponds to vector DNAs before
injection. The subsequent ladders correspond to DNAs extracted from ischaemic and non-ischaemic legs of two representative animals at each cycle of
selection. An arrow indicates the ghrelin band. (e) Real-time PCR quantification of the relative amount of the ghrelin cDNA over the total AAV DNA at each
cycle of selection. Bars represent mean±s.e.m. (n¼ 12 per group per cycle). Student’s t-test; *Po0.05, **Po0.01.
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in Supplementary Table 2) into the tibialis anterior muscles of
CD1 mice (1 1010 viral genomes (vg) per limb); 2 weeks after
injection, the left femoral artery was resected to induce unilateral
ischaemia. After 2 additional weeks, the vector cDNAs from both
the ischaemic and non-ischaemic leg were recovered by PCR
using a primer pair flanking the cDNA inserts, pooled according
to treatment and re-cloned into AAV vector plasmids to start an
additional selection cycle. Selection was applied for three iterative
cycles (n¼ 12 per group per pool per cycle).
The PCR ladders obtained from the input viral lysate and from
the DNAs recovered from the legs of two representative animals
at each selection cycle are shown in Fig. 1d. The procedure
led to the progressive enrichment of a single cDNA species
(quantification in Fig. 1e). DNA sequencing identified it as the
cDNA coding for the neuroendocrine peptide ghrelin. None of
the other 70 genes considered in original group of 100, which
were analysed in pools of 35, were significantly enriched
compared with ghrelin (not shown).
Ghrelin improves muscle recovery after hindlimb ischaemia.
We verified that AAV9-ghrelin exerted a direct protective effect
after ischaemic muscle injury, in agreement with previous
findings using the ghrelin peptide22. Injection of AAV9-ghrelin
HE
DA
PI
Le
ct
in
Tu
n
e
l
600 ***
**
AAV9-control
AAV9-ghrelin (day 7) AAV9-control
AAV9-ghrelin
AAV9-control
AAV9-ghrelin
AAV9-control
AAV9-ghrelin
AAV9-control
AAV9-ghrelin
AAV9-control
AAV9-ghrelin
Ischemia + AAV9-control
Ischemia + AAV9-ghrelin
No ischemia
Ischemia + AAV9-control
Ischemia + AAV9-ghrelin
No ischemia
AAV9-ghrelin (day 21)
AAV9-ghrelin
25
20
15
10
5
0
20
15
10
5
0
Day 21 Day 21
** **
**
AAV9-ghrelin
AAV9-control
AAV9-control
500
400
300
G
hr
el
in
/G
AP
DH
(fo
ld
 o
ve
r 
e
n
do
ge
no
us
)
Is
ch
em
ic
 le
si
on
 p
er
 fi
el
d 
(%
)
In
fla
m
m
at
or
y 
ce
ll
in
filt
ra
tio
n 
pe
r f
ie
ld
 (%
)
Tu
n
e
l+
nu
cl
ei
 (%
)
m
R
N
A/
G
AP
DH
(fo
ld
 o
ve
r 
co
n
tro
l)
Ce
nt
ra
l n
u
cl
ei
 p
er
 fi
el
d
Fi
br
es
 (%
)
Cl
in
ica
l s
co
re
BA
X/
BC
L-
2 
m
R
N
A
100
10 45
40
35
30
25
20
15
10
5
0
40
30
20
10
0
Day 7
Day 7
Day 21
25
20
15
10
5
0
*
*
**
* * *
*****
80
60
40
20
0
9
8
7
6
5
4
3
2
1
0
2.0 50 25
AAV9-control AAV9-ghrelin
20
15
10
0
Fibre cross-sectional area (μm2)
Time after ischemia (days)10
0
20
0
30
0
40
0
50
0
60
0
70
0
80
0
90
0
1,
00
0
1,
10
0
1,
20
0
1,
30
0
1,
40
0
1,
50
0
10
0
20
0
30
0
40
0
50
0
60
0
70
0
80
0
90
0
1,
00
0
1,
10
0
1,
20
0
1,
30
0
1,
40
0
1,
50
0
5
25
20
15
10
4
3
2
1
0
2 7 21
* **
0
5
40
30
20
10
0
1.5
0.5
1.0
0
IL6 IL-1 TNF
Figure 2 | Ghrelin improves muscle functional recovery after femoral artery resection. (a) Real-time PCR quantification of ghrelin mRNA in tibialis
anterior muscles transduced with 1 1011 vg of AAV. Values are normalized for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and expressed as
fold over endogenous (n¼ 5). (b) Haematoxylin-eosin (HE) staining of tibialis anterior muscles at day 21 after femoral artery resection. Scale bar, 50 mm.
(c) Quantification of ischaemic lesion in muscles injected with AAV9-ghrelin. Values are expressed as percentage per field (n¼ 7 per group, four fields
counted for each animal). (d) Quantification of inflammatory cell infiltration. Values are expressed as percentage of cells per field (n¼ 7 per group, four
fields per animal). (e) Expression levels of inflammatory cytokines, analysed by real-time PCR, at day 7 after transduction and surgery. Values are
normalized for GAPDH and expressed as fold over untreated (n¼ 5). (f,g) Analysis of apoptosis by TUNEL. Representative images (f) and quantification
(g) of TUNEL-positive nuclei in the muscle areas adjacent to the lesions (n¼ 5). Red: apoptotic nuclei; blue: 40-6-diamidino-2-phenylindole (DAPI); green:
lectin-stained muscle fibres. Scale bar, 100mm. (h) Ratio between BAX and BCL-2 mRNAs in AAV9-injected muscles, 7 days after femoral artery resection.
Values are normalized for GAPDH and expressed as fold over untreated (n¼ 5). (i) Number of fibres with central nuclei per field as a marker of muscle
regeneration at 21 days after treatment (n¼ 7 per group, four fields per animal). (j) Fibre size analysis after ischaemia and AAV9 injection. The histograms
show the distribution of the fibre cross-sectional areas (mm2); a normal distribution curve is superimposed. Analysis of 20 cross-sections from six animals
per group was performed. Po0.01. (k) Limb function analysed at days 2, 7 and 21 after treatment by assigning a clinical score, according to established
criteria (n¼ 25 per group)60. All values are mean±s.e.m. Pairwise comparison was performed with the Student’s t-test (c,d,g,i); one-way analysis of
variance (ANOVA) and Bonferroni/Dunn’s post hoc test were used to compare multiple groups (a,e,h); two-way ANOVA was used in k; the Kolmogorov–
Smirnov test was used to compare distributions in j. *Po0.05, **Po0.01, ***Po0.001 relative to control.
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(1 1011 vg) in the tibialis anterior muscle of CD1 mice
immediately after femoral artery resection led to robust
transgene expression over time (Fig. 2a), which prevented fibre
degeneration (Fig. 2b), reduced size of the ischaemic lesion,
inflammatory cell infiltration and expression of several
inflammatory cytokines (Fig. 2c,d,e, respectively). Preservation
of muscle mass correlated with marked protection from apoptosis
(Fig. 2f–h) and improved muscle regeneration, indicated by the
significantly increased number of centronucleated fibres (Fig. 2i)
and the right-skewed distribution of the fibre cross-sectional area
(Fig. 2j), eventually resulting in improved limb function in
ghrelin-expressing muscles (Fig. 2k). The myoprotective effect of
ghrelin correlated with increased numbers of both capillaries and
arterioles, likely as a consequence of tissue survival and
regeneration (Supplementary Fig. 2c).
Ghrelin preserves cardiac function after MI. Next, we wanted to
assess whether AAV9-ghrelin protected the heart after MI.
Adult CD1 mice (n¼ 25 per group) underwent permanent left
descendent coronary artery ligation and were immediately
injected with 1 1011 viral particles of AAV9-ghrelin or of a
control AAV9 vector, in the peri-infarcted area. Ghrelin mRNA
was found overexpressed in the heart, already at day 2 after vector
injection (B20-fold), and remained high for at least 3 months
(160-fold; Fig. 3a); at 15 days, AAV-ghrelin genomes and trans-
gene expression were also observed in the liver (Supplementary
Fig. 3a,b, respectively). Consistently, both intracardiac and
plasmatic levels of des-acyl ghrelin were significantly increased in
the AAV9-ghrelin-injected animals (Fig. 3b,c, respectively).
As evaluated by echocardiography at 2, 7, 30, 60 and 90 days
post MI, both the left ventricle (LV) ejection fraction (Fig. 3d)
and the LV fractional shortening (Fig. 3e) were significantly
preserved in the infarcted mice injected with AAV9-ghrelin.
These parameters were maintained over time (at day 90 post MI,
LV ejection fraction: 30.8±3.4% versus 50.7±2.7%; LV fractional
shortening: 14.9±1.8% versus 26.0±1.6% in control and ghrelin-
transduced animals, respectively). At both 1 and 3 months after
cardiac gene transfer, the LV end-systolic anterior wall thickening
(Fig. 3f) of the infarcted hearts injected with AAV9-ghrelin
was also markedly improved (20.7±2.8% versus 37.1±5.4 and
15.4±3.3% versus 30.8±4.5% in control and ghrelin-transduced
animals, respectively at day 30 and 90 after infarction). Finally,
the diastolic LV internal diameter (Fig. 3g) was significantly larger
in the control animals at both 1 and 3 months after MI.
Representative M-mode echocardiograms at the latter time are
shown in Fig. 3h.
Morphometric analysis on trichromic-stained heart sections at
day 90 indicated that AAV9-ghrelin-treated mice showed
significant preservation of LV-contractile tissue and reduction
of the fibrotic area (infarct size: 51.3±4.8% versus 27±1.9% of
the LV in control and ghrelin-transduced animals, respectively;
Fig. 3i,j).
Consistent with echocardiographic and morphometric
observations, AAV9-ghrelin significantly counteracted the
characteristic pattern of gene expression typically associated with
pathological LV remodelling, consisting in the overexpression of
a-MHC and cardiac natriuretic peptides (BNP and NPPA), and in
decreased levels of b-MHC, SERCA2a, RYR2 and PGC1a (Fig. 3k).
Finally, at day 7, post MI, when inflammatory cell massively
infiltrated the heart of control mice, ghrelin significantly blunted
this effect (n¼ 5 per group; Supplementary Fig. 4a,b), with a
parallel decrease in the levels of the inflammatory cytokines
IL-1b, IL6 and TNFa (Supplementary Fig. 4c).
Collectively, these results indicate that ghrelin is cardio-
protective after MI, reducing infarct size and preserving
myocardial viability and function.
Ghrelin protects myocardial cells from apoptosis. The
preservation of cardiac tissue observed in hearts injected with
AAV9-ghrelin following MI suggested that the factor, similar to
what had been observed in the skeletal muscle, might protect
cardiomyocytes from ischaemia-induced apoptosis. Indeed, the
number of apoptotic nuclei in the animals injected with this
vector at day 2 after MI was markedly decreased (n¼ 8 per group;
30.7±5.4% versus 8.3±4.6% TUNEL (TdT-mediated dUTP
nick-end labelling)-positive cells in control and ghrelin-
transduced animals, respectively; representative images and
quantification in Fig. 4a,b, respectively).
A similar protective effect of AAV9-ghrelin vector (MOI:
5 104 vg per cell) was also observed in neonatal rat ventricular
cardiomyocytes treated with the cardiotoxic agents isoproterenol
or doxorubicin, by quantifying the number of TUNEL-positive
nuclei (Fig. 4c,d). The in vitro antiapoptotic effect of AAV9-
ghrelin was confirmed by a reduction in caspase 3/7 activation in
both neonatal cardiomyocytes and HL-1 cells, after 20 h of
doxorubicin treatment (0.5 and 1 mM, respectively; Fig. 4e,f).
Ghrelin stimulates autophagy after MI. Next, we wondered how
ghrelin exerted its protective effect after MI. Multiple evidence
indicates that a powerful mechanism protecting the heart
against ischaemic damage is macroautophagy (hereafter referred
to as autophagy)13. In the infarcted hearts transduced with
AAV9-ghrelin, we found an increased conversion of the soluble
LC3-I protein to lipid-bound LC3-II, which associated with
the formation of autophagosomes (representative blots and
quantification for AAV9-ghrelin and AAV9-control hearts in
Fig. 5a,b, respectively). Consistent with this observation, the
mRNAs of genes involved in the autophagic pathway, including
BECLIN1, MAP1LC3A and ATG12, were all significantly induced
in the AAV9-ghrelin-transduced, infarcted hearts (Fig. 5c). In the
same hearts, the AMP-activated protein kinase (AMPK), a key
regulator of energy metabolism, which also regulates cardiac
autophagy23, was also found to be activated (Fig. 5d,e).
To directly visualize the autophagic flux in the infarcted hearts,
we generated an AAV9 vector expressing the monomeric red
fluorescent protein (mRFP)-enhanced green fluorescent protein
(EGFP) tandem fluorescent-tagged LC3 protein, derived from the
ptfLC3 plasmid24, in which green, but not red, fluorescence is
sensitive to the acidic pH within the autolysosome. This vector
was administered, together with AAV9-control or AAV9-ghrelin
(1 1011 vg per animal for each vector), immediately after left
anterior descending (LAD) coronary artery ligation (n¼ 6 per
group), or in non-infarcted animals (n¼ 6 per group). At day 7
after transduction, the number of LC3-positive vesicles, and, in
particular of those showing only red fluorescence, was
significantly increased in infarcted hearts injected with AAV9-
ghrelin (Fig. 5f,g). This indicated that ghrelin stimulates
autophagic flux.
In the heart, the levels of the GOAT enzyme are low5 and thus
the observed induction of in vivo autophagy was probably
mediated by unmodified ghrelin. To clarify the relative
contribution of the acyl and des-acyl forms of the protein in the
promotion of autophagy, we treated rat neonatal cardiomyocytes,
previously transfected with the ptfLC3 plasmid, with either of the
two peptides. Both of these, but most importantly, des-acyl ghrelin,
increased the number of autophagosomes and promoted
autophagic flux; this effect was evident both in complete medium
and upon serum and glucose starvation, a condition known to
increase autophagy (Fig. 5h,i). Superimposable results were
obtained using the HL-1 cardiac cell line (Supplementary Fig. 5a,b).
Both acyl and des-acyl ghrelin also increased the levels of
endogenous LC3 lipidation in HL-1 cells (9.8±1.3% cells
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containing more than 30 LC3-positive vesicles in basal conditions
versus 23.8±1.7% and 27.3±2.5% after treatment with the two
peptides, respectively; Fig. 5l,m). When the cells were treated
with the lysosomotropic agent, chloroquine, both peptides still
increased vesicle formation (number of LC3B-positive cells:
37.3% in the absence of treatment; 44.4% and 47.2% after
addition of acyl or des-acyl ghrelin, respectively), thus confirming
that both forms of ghrelin were capable of inducing the auto-
phagic flux. Finally, cells treatment with the phosphatidylinositide
3-kinase (PI3K) inhibitor wortmannin blocked autophagosomes
formation in both acyl and des-acyl ghrelin-treated HL-1 cells.
Collectively, these results indicate that ghrelin and, in
particular its unmodified form, is an effective inducer of
autophagy in isolated cardiomyocytes and in vivo, thus suggesting
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a mechanism of action independent from GHSR-1a receptor
activation.
Ghrelin stimulates autophagy after hindlimb ischaemia. We
also studied the effect of ghrelin in inducing autophagy in the
skeletal muscle after hindlimb ischaemia. In CD1 mice trans-
duced with AAV9-ghrelin at 7 days after femoral artery resection
(cf. above), the amount of p62, a protein rapidly degraded during
autophagy, was significantly reduced in comparison to AAV9-
control-transduced mice (Supplementary Fig. 6a and b), while the
mRNA levels of BECLIN1, MAP1LC3A and ATG12 were all
induced (Supplementary Fig. 6c). As in cardiac myocytes, both
acyl and des-acyl ghrelin induced autophagic flux in C2C12
myoblasts, as concluded by the increased number of mRFP-LC3
autolysosomes in cells transfected with the ptfLC3 plasmid
(Supplementary Fig. 6d,e). Finally, in cells treated with
chloroquine to induce accumulation of autophagosomes,
ghrelin significantly increased conversion of LC3-I to LC3-II
(Supplementary Fig. 6f,g).
Autophagy inhibition blocks the protective effect of ghrelin.
To investigate whether there was a direct correlation between the
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anti-apoptotic effect of ghrelin an its capacity to induce
autophagy, we inhibited autophagy in HL-1 cells using either
wortmannin or an small interfering RNA (siRNA) against ATG5,
essential for the initial phase of formation of autophagic
vesicles25, and then evaluated the outcome of these treatments on
the anti-apoptotic effects of ghrelin. In both conditions, the
inhibition of autophagy abrogated the protective effects of both
acyl and des-acyl ghrelin against doxorubicin-induced apoptosis
(20 h, 1 mM), as assessed by measuring caspase 3/7 activation
(Figs 6a for wortmannin and Fig. 6b,c for RNA interference).
These results indicate that autophagy is essential in mediating the
survival effect of ghrelin on cardiomyocytes.
Ghrelin removes dysfunctional mitochondria. One of the
specific functional consequences of the induction of autophagy is
the removal of dysfunctional cellular organelles. In particular,
in the heart, the elimination of swollen and malfunctioning
mitochondria by autophagy (mitophagy) is essential to maintain
tissue homeostasis26. We found that treatment of HL-1
cardiomyocytes with acyl and even more with des-acyl ghrelin
markedly increase the number of autophagic vesicles containing
mitochondria. This effect was particularly evident after starvation
(representative images of LC3-positive vesicles containing
autophagocytosed mitochondria and quantifications in Fig. 7a,b,
respectively). The peptides still increased the number of
mitophagy vesicles in the presence of chloroquine, again
indicating stimulation of the mitophagic flux.
We further investigated the induction of autophagy and, in
particular, the removal of damaged mitochondria by transmission
electron microscopy in HL-1 cells. We found that acyl and, in an
even more pronounced manner, des-acyl ghrelin increased
autophagy in both complete medium and under starvation
(Fig. 7c and Supplementary Fig. 7a, respectively, for representa-
tive images and Fig. 7d and Supplementary Fig. 7b for
quantification). Of note, clear mitochondrial structures included
in autophagic vesicles were detected upon des-acyl ghrelin
stimulation in both culture conditions. Upon treatment with
chloroquine, numerous mitochondrial structures at different
stages of degradation were detected as included in autophago-
somes in cells treated with both acyl and des-acyl ghrelin.
Chloroquine also favoured the formation of large-size autophagic
vesicles containing cellular components; in particular, in cells
stimulated with des-acyl ghrelin, damaged mitochondria were
identifiable within very large autophagosomes (Fig. 7c and
Supplementary Fig. 7a). Taken together, these electron micro-
scopy results clearly confirm the property of the two peptides,
and, in particular, of des-acyl ghrelin, to trigger autophagy and
the removal of dysfunctional mitochondria.
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Figure 6 | Inhibition of autophagy abolishes the protective effect of ghrelin. (a) Pretreatment with wortmannin blocks the protective effect of
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Figure 5 | Reduced apoptosis is paralleled by increased autophagy in ischaemic cardiomyocytes overexpressing ghrelin. (a,b) LC3 lipidation
(conversion from LC3-I to LC3-II) in the left ventricles of transduced hearts harvested 2 days after MI. Representative western blot (a) and densitometric
analysis (b; n¼ 6). (c) Quantification of MAP1LC3A, BECLIN1 and ATG12 mRNA levels in the left ventricles of transduced hearts at 2 days after MI. Values
are normalized for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and expressed as fold over untreated (n¼ 8). (d,e) AMPK phosphorylation in the
left ventricles of transduced hearts harvested 2 days after MI. Representative western blot (d) and densitometric analysis (e) of total AMPK and phosphor
(pAMPK; n¼ 6). (f) Heart sections of mice injected with AAV9-mRFP-EGFP-LC3 and AAV9-control or AAV9-ghrelin and submitted or not to MI.
Autophagosomes appear yellow in the merged image, whereas autolysosomes appear red. Scale bar, 100mm. (g) Quantification of EGFP and mRFP
LC3-positive dots per field, using the ImageJ software (n¼ 6). (h) Primary rat neonatal cardiomyocytes transfected with the mRFP-EGFP tandem
fluorescent-tagged LC3 plasmid (ptfLC3) and, 48 h later, treated for 4 h with acyl ghrelin, des-acyl ghrelin (both 1 mM) or vehicle in complete or starving
medium. Scale bar, 10mm. (i) Quantification of EGFP and mRFP LC3-positive dots per cell, using the ImageJ software (n¼ 30 cells per group).
(l) Representative immunofluorescence staining for LC3B (green) in HL-1 cells treated for 4 h with acyl ghrelin, des-acyl ghrelin (both 1 mM) or vehicle in the
presence or absence of chloroquine (10 mM) or wortmannin (0.5mM). Scale bar, 50mm. (m) Quantification of the cells with a high number (430) of
LC3B-positive vesicles, expressed as % of the total number of cells (n¼ 30 cells per group). All values are mean±s.e.m. One-way analysis of variance
(ANOVA) and Bonferroni/Dunn’s post hoc test were used to compare multiple groups (b,c,e,g,i,m). *Po0.05, **Po0.01, ***Po0.001 relative to control.
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Dysfunctional mitochondria determine macromolecular
damage by increased reactive oxygen species (ROS) production27.
Consistent with the protective role of ghrelin-induced autophagy
of dysfunctional mitochondria, intact mitochondria from starved
neonatal cardiac ventricular myocytes treated with des-acyl
ghrelin generated significantly less H2O2 (an indicator of ROS
generation) using either glutamate and malate or succinate as
oxidative substrates (Fig. 7e). No significant effect on ROS
production was exerted by acyl ghrelin in this assay. Moreover,
we observed a prominent upregulation of PGC1a transcript
induced by des-acyl ghrelin, indicating synthesis of novel
mitochondrial components, to replace degraded mitochondria
(Fig. 7f).
This capacity of ghrelin to remove dysfunctional mitochondria
is fully consistent and may well support the observed effect of the
peptide in the protection of the infarcted myocardium.
Mock
Basal GM S PCM
0
1
2
3
4
5 *
Acyl ghrelin (1 μM)
Des-acyl ghrelin (1 μM)
**
0
2
4
6
10
8
–
–
Starvation: + ++
– ––
– ––
+ ++
*
**
–
–
–
–
*
0
2
3
5
4
1
Mock
Mitochondria
ER
Des-acyl ghrelin 
N
N
Chloroquine + des-acyl ghrelin
N
N
Chloroquine + acyl ghrelin 
N
Chloroquine
**
m
R
N
A/
G
AP
DH
 
(fo
ld 
ov
er 
co
ntr
ol)
Mitochondria
Mock
Des-acyl ghrelin (1 μM)
Acyl ghrelin (1 μM)
%
 O
f a
ut
op
ha
go
so
m
es
a
re
a
 (fo
ld 
ov
er 
co
ntr
ol) **
*
0
4
5
2
3
1
Chloroquine
(10 μM):
***
**
Autophagic vesicle
containing a
mitochondrion
Mock
*
**
Damaged
mitochondrion
Autophagic
vesicles
Autophagic
vesicles
Autophagic
vesicle
Autophagic
vesicle
MitochondriaAutophagic
vesicle
Damaged
mitochondrion
Chloroquine
(10 μM):
M
ito
ph
ag
y 
ve
sic
le
s
(%
 of
 to
tal
)
M
ito
ch
on
dr
ia
l H
2O
2
sy
nt
he
sis
 ra
te
(nm
ol 
U C
S–
1  
m
in
1 ) 
HL-1 cells
Control
Acyl ghrelin 
–– – + + +
HL-1 cells
HL-1 cells
Neonatal rat ventricular myocytes
Neonatal rat ventricular myocytes
PGC1α
Des-acyl ghrelin (1 μM)
Acyl ghrelin (1 μM)
Des-acyl ghrelin (1 μM)
Acyl ghrelin (1 μM)
Chloroquine Chloroquine + acyl ghrelin Chloroquine + des-acyl ghrelin
Des-acyl ghrelin Acyl ghrelin 
Starvation + des-acyl ghrelin 
Control
Starvation Starvation +acyl ghrelin 
Mitotracker LC3 HL-1 cells
Figure 7 | Ghrelin reduces ROS accumulation removing dysfunctional mitochondria. (a) Hl-1 cells were incubated in normal or starving conditions with
acyl ghrelin, des-acyl ghrelin (1 mM) or vehicle in the presence or absence of chloroquine (10 mM) for 4 h. Mitochondria were labelled with MitoTracker
Orange for 30min at 37 C. Cells were then fixed, stained for LC3B and imaged using a confocal laser-scanning microscope. Representative images of
mitochondria (red), autophagosomes (LC3B, green) and their overlap are shown. For each picture, an enlargement of the overlap image is displayed,
showing the presence or absence of co-localizing mitochondria and autophagosomes. Scale bar, 10 mm. (b) Quantification of the percentage of
LC3B-positive autophagosomes co-localizing with mitochondria (n¼ 30 cells per group). (c) Representative electron micrographs of HL-1 cells incubated in
complete medium with acyl ghrelin, des-acyl ghrelin (both 1 mM) or vehicle in the presence or absence of chloroquine (10 mM) for 4 h. For each picture,
an enlargement of the image is displayed, showing the presence of normal or damaged mitochondria (indicated by arrowheads) and autophagic vesicles
(indicated by arrows). Scale bar, 1mm. (d) Quantification, from the electron microscopy pictures, of the cytoplasmic areas containing autophagic structures
per section. Values are expressed as percentages and normalized over mock conditions (n¼ 10 per condition). (e) Quantification of reactive oxygen species
(ROS) production in intact mitochondria isolated from neonatal rat cardiomyocytes after 48 h of starvation in the absence or presence of acyl or des-acyl
ghrelin (both 1mM). After addition of either ultrapure H2O or respiration substrates, state 4-mitochondrial respiration H2O2 production was measured,
n¼4 (GM, glutamate/malate; S, succinate; PCM, palmitoyl-L-carnitine/malate). (f) Quantification of PGC1a mRNA expression levels in rat neonatal
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compare multiple groups (b,d,e,f). *Po0.05, **Po0.01, ***Po0.001 relative to control.
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Discussion
In contrast to phenotypic selection (for example, using phage
display libraries), functional screening of genetic libraries in vivo
is in its infancy. The generation of cDNA28–30, ribozyme31–33
and short hairpin RNA34,35 libraries has been achieved in
gammaretroviral vectors. However, these vectors only transduce
replicating cells, whereas most cells in the body lie outside the cell
cycle. Libraries generated in lentiviral vectors can be screened
in vivo, but their utilization is limited to specific permissive cell
types36,37, which do not include those of interest in the
cardiovascular system (cardiomyocytes, skeletal muscle fibres
and endothelial cells). First-generation adenoviral vectors have
also been engineered to express cDNA libraries38–40, but their
high immunogenicity in vivo leads to the rapid elimination of the
transduced cells, thus preventing long-term screenings41–43.
Here, for the first time, we report on the feasibility of an in vivo
functional selection strategy (FunSel), which can be performed
over relatively long periods of time and in tissues that are usually
refractory to conventional gene transfer. This is rendered possible
by the use of AAV vectors, which show exquisite tropism for
cardiomyocytes, skeletal muscle fibres, retinal cells, neurons and
b-cells in the pancreas (reviewed in ref. 44). Of note, these cell
types are the major targets of highly prevalent degenerative
disorders, including heart failure, blindness, diabetes and
neurodegeneration. Our results indicate that: (i) multiple AAV
vectors can be packaged simultaneously, (ii) the infectivity of each
vector in such mixtures is maintained in vivo, (iii) transgene
expression is proportional to vector dilution in the transducing
preparation and (iv) vector pool complexity up to 50 vectors per
pool allows relatively robust levels of transgene expression. Our
choice to screen for secreted factors poses an additional hurdle to
the screening process itself, as a putatively positive factor is
expected to exert its beneficial effect beyond the transduced cells,
a possibility that we also took into account in our mathematical
simulations. Our choice, however, was dictated by the eventual
possibility of administering the identified factor as a recombinant
protein or synthetic peptide, without necessarily relying on viral
vector delivery.
FunSel is based on an in vivo competitive process between a
beneficial gene and those that are neutral or detrimental within
the same pool; as the procedure is iterative, the ultimate factor
identified is the best performer in the pool. The survival
advantage upon which FunSel is based does not necessarily
coincide with a direct effect of the transgene on the transduced
cells through the regulation of genes directly promoting cell
survival. Instead, the effect of the selected transgene might be
indirect, for example, ensuing as the consequence of improved
blood perfusion, or the regulation of inflammation or immune
reactivity, or due to the multiplication of the transduced cells at
the expense of other cells, to name but a few of the possible
selection mechanisms. In vivo, most factors exert their function
through pleiotropic mechanism; FunSel thus offers the advantage
of screening for beneficial effects that are cumulative. Indeed, here
the application of FunSel to search for factors selected after acute
ischaemia led to the identification of ghrelin as a protein that
induces autophagy, protects from apoptosis and ameliorates
energy metabolism, three functions that are strictly connected
and eventually improve function under ischaemic conditions.
Converging evidence over the last few years has indicated that
autophagy exerts beneficial effects in the heart17. Cardiomyocytes
have a very long life, often coinciding with the whole life of the
organism45, and an extremely high metabolic demand. In these
cells, the recycling of dysfunctional organelles, in particular
mitochondria, is essential to maintain cardiac energy homeostasis
and to preserve function and vitality under stress. Loss of
autophagy in Atg5 / knock out mice14 and in patients with an
inherited defect in the lysosomal protein Lamp-2 (ref. 20) leads to
cardiomyopathy and heart failure; the proapoptotic kinase
Mst1 induces cardiac dysfunction by impairing autophagy in
cardiomyocytes19. On the contrary, induction of autophagy
protects against ischaemia/reperfusion injury18,46, limits cell
death and tissue damage following acute MI47, represents a
pro-survival mechanism in chronically ischaemic myocardium48
and constitutes a quality control mechanism to remove damaged
mitochondria49. Thus, the promotion of the autophagic response
over time stands as a novel, therapeutic option to mitigate post-
infarction LV dilation and cardiac dysfunction. In line with these
notions, our observations indicate that hearts expressing ghrelin
show highly reduced cardiomyocyte apoptosis immediately after
coronary artery ligation and persistence of autophagic flux in the
infarct border zone at later times; both findings correlate with
markedly improved cardiac function up to 3 months after MI.
The short-term, antiapoptotic effect of ghrelin is consistent with
previous findings on isolated cardiomyocytes and cardiomyocyte
cell lines50.
As the original discovery of ghrelin as a peptide with orexigenic
properties6, it soon became evident that this molecule also exerts
beneficial function in the cardiovascular system, including
improved inotropic response, cardioprotection and reduction of
the inflammatory response (reviewed in ref. 51); patients with
heart failure receiving acyl ghrelin (intravenous, twice a day for
3 weeks) showed significantly improved cardiac function52.
Our results now provide a mechanism by which ghrelin exerts
its long-term benefit in the heart.
Our novel finding that ghrelin induces autophagy and, in
particular, the removal of dysfunctional mytochondria in
cardiomyocytes is consistent with a number of biochemical
studies showing that ghrelin activates various signal transduction
pathways in these cells (including MAP kinases, PI3K/Akt and
AMPK50,53–56) also known to regulate at various extents these
processes. In particular, we found that infarcted hearts treated
with ghrelin showed increased AMPK activity, an observation
that is fully consistent with the capacity of this kinase to limit
apoptotic activity and stimulate protective cardiac autophagy
after ischaemic injury23. Previous work has shown that
AMPK also triggers the removal of damaged mitochondria and
induces mitochondria biogenesis through PGC1a activation57, an
observation in keeping with the increased levels of PGC1a we
observed in the ghrelin-treated hearts.
Which receptor mediates the autophagic response of skeletal
muscle fibres and cardiomyocytes to ghrelin? Mounting evidence
over the last few years has indicated that several of ghrelin
activities are not mediated by its only discovered receptor,
GHSR-1a, which is selective for acyl ghrelin and does not bind the
native peptide6. Indeed, both acyl and des-acyl ghrelin inhibit
apoptosis and activate the PI3K/Akt pathway in H9c2
cardiomyocytes, which do not express GHSR-1a, and protect
the skeletal muscle of GHSR-1a knockout mice from fasting-
induced atrophy50,55. In our study, induction of autophagy was
observed in vivo in the heart, where AAV vectors express the
native protein and the GOAT enzyme is poorly expressed. In
addition, both autophagy and mitophagy in cultured myocardial
cells were stimulated more efficiently by des-acyl than by acyl
ghrelin. Taken together, these findings strongly indicate that the
pro-autophagic activity of ghrelin is mediated by a yet
unidentified receptor, distinct from GHSR-1a. Fully consistent
with these observations, the effects of AAV9-ghrelin are
maintained after MI in GHSR-1a knockout mice (unpublished
observations). Surprisingly, only des-acyl ghrelin protects
cardiomyocytes from ROS induced by energetic substrates. This
finding is in keeping with previous data reporting that des-acyl
ghrelin, but not acyl ghrelin, prevents ischaemia-induced ROS
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production in skeletal myocytes and upregulates anti-oxidant
enzymes58.
The identification of the exact molecular pathways triggering
myocardial autophagy by des-acyl ghrelin will await the
identification of the long sought, but still elusive, receptor
binding of this native form of the peptide.
Methods
Generation of the AAV library. All cDNAs were amplified from the original
cloning plasmids (modified pBluescript SK (þ )/modified Bluescript1 and pFlcI) by
PCR with specific primers (reported in Supplementary Table 3), to insert the XhoI
and NotI restriction sites at the 50 and 30 ends of each cDNA. The amplified
sequences were individually cloned into the pZac2.1 vector (Gene Therapy
Program, Penn Vector core, University of Pennsylvania, USA) under the control
of the CMV IE promoter. The AAV-control vector carried an empty polylinker.
The nucleotide sequence of each clone was verified.
Production and purification of AAV vectors. The AAV vectors were prepared
by the AAV Vector Unit at the ICGEB Trieste (http://www.icgeb.org/avu-core-
facility), according to established procedures59. Briefly, AAV vectors of serotypes
2 and 9 were generated in HEK293T cells, using a triple-plasmid co-transfection for
packaging. Viral stocks were obtained by CsCl2-gradient centrifugation. Titration
of AAV viral particles was performed by real-time PCR quantification of the
number of viral genomes, measured as CMV copy number. The viral preparations
had titre between 1 1013 and 5 1013 vg per ml.
Animal studies. Animal care and treatment were conducted in conformity with
institutional guidelines in compliance with national and international laws and
policies (EEC Council Directive 86/609, OJL 358, 12 December 1987), upon
approval by the ICGEB Animal Welfare Board and Ethical Committee as well as
by the Italian Minister of Health. CD1 mice and Wistar rats were obtained from
Harlan and maintained under controlled environmental conditions.
In vivo AAV library screening. Pools of plasmids, mixed in equimolar amounts,
were used for batched AAV2 vector production. Each vector preparation (30 ml,
containing 1 1010 vg per leg) was injected bilaterally into the tibialis anterior
muscle of 3-month-old female CD1 mice (n¼ 12); 2 weeks later the animals were
submitted to unilateral femoral artery resection as detailed in the next paragraph.
After 2 additional weeks, the animals were killed and DNA was extracted from the
injected muscles of both legs using the DNeasy Blood and Tissue kit (Qiagen). The
cDNA inserts from the extracted DNA were amplified by 25 PCR cycles using
primers annealing on the common pZac2.1 vector sequence and flanking the
multiple cloning site. Primer sequences (pZac2.1 FW and RV) are reported in
Supplementary Table 3. Part of the amplified DNA was visualized by 1% agarose
gel electrophoresis (Fig. 1c); the rest was digested with XhoI and NotI and re-cloned
into the pZac2.1 vector to generate a new AAV9 vector preparation. The cycle was
repeated for a total of three times.
Hindlimb ischaemia. For in vivo AAV vector selection, the AAV9-Pool vector
(30 ml, 1 1010 vg per animal) was bilaterally delivered to the tibialis anterior
muscles of 3-month-old female CD1 mice (n¼ 12). After 15 days, animals were
submitted to unilateral femoral artery resection.
For the analysis of AAV9-ghrelin effects, the same procedure was adopted, but
50ml of recombinant AAV vectors (AAV9-control or AAV9-ghrelin; 1 1011 vg
per animal) were injected (female 3-month-old CD1 mice, n¼ 25 per group).
Before femoral artery resection, CD1 mice were anesthetized by i.p. injection of
ketamine (100mg kg 1) and xylazine (10mg kg 1) and placed on a warming pad
to maintain core body temperature at 37 C. Unilateral hindlimb ischaemia was
induced by resecting a 2.5-cm segment of the left femoral artery. The tibialis
anterior muscles of animals injected with AAV9-control or AAV9-ghrelin were
collected at 7 (n¼ 7 per group) and 21 days (n¼ 18 per group) after resection.
In vivo evaluation of limb function and ischaemic damage was performed at days 2,
7 and 21 post ischaemia by assigning a numeric score, according to established
criteria60.
Myocardial infarction. MI was produced in female CD1 mice (8to 10-week old),
by permanent LAD coronary artery ligation as already described61. In details, mice
were anesthetized with ketamine (100mg kg1) and xylazine (10mg kg 1), placed
on a warming pad to maintain body temperature at 37 C and endotracheally
intubated and connected to a rodent ventilator (Model 131, Nemi Scientific Inc.).
The beating heart was accessed via a left thoracotomy; after removing the
pericardium, the heart was exposed and the descendent branch of the LAD
coronary artery was visualized by a stereomicroscope (Leica) and ligated with an
8-0 silk suture. Ligation was confirmed by the whitening of the anterior wall
of the LV. Immediately after LAD ligation, 30 ml of recombinant AAV vector
(AAV9-ghrelin or AAV9-control; 1 1011 vg per animal; n¼ 25 per group)
were administered into the infarct border zone using a tuberculin syringe (30G;
Roche). The chest was closed and the mice moved to a prone position on a heating
pad until they recovered spontaneous breathing. Echocardiography, as detailed
below, was performed after 2, 7, 30, 60 and 90 days and the hearts were collected at
2 (n¼ 8 animals per group), 7 (n¼ 5 animals per group) and 90 days (n¼ 12
animals per group) after infarction.
Echocardiography. To analyse LV function and dimension, transthoracic two-
dimensional echocardiography was performed in mice sedated with 5% isoflurane,
using the Vevo 770 Ultrasound (Visualsonics), equipped with a 30-MHz linear
array transducer. M-mode tracing were used to measure LV anterior and posterior
wall thickness and LV internal diameter at end-systole and end-diastole in short
axis view, which were used to calculate fractional shortening and ejection fraction.
Histology and immunofluorescence. At the end of the studies, animals were
killed and muscles or hearts were collected and washed in PBS. Tissue samples
were snap frozen or fixed in 4% formaldehyde and embedded in paraffin for
immunofluorescence or histological analysis. Frozen sections of the tissues were
used for TUNEL assay (described below), whereas paraffin-embedded sections of
muscles recovered at day 21 post ischaemia or hearts recovered at day 7 post MI,
were stained with haematoxylin-eosin for inflammatory cell infiltration analysis or
evaluation of ischaemic lesion area and fibre regeneration after hindlimb ischaemia
(four randomly chosen fields per tissue transversal section were quantified using
the ImageJ software). A total of seven animals per group were analysed. The hearts
collected 90 days after infarction were submitted to Azan’s trichrome staining
(Bio-Optica), according to the manufacturer’s protocol. Infarct size was measured
on stained sections as the percentage of (endocardialþ epicardial circumference of
infarct area) (endocardialþ epicardial circumference of LV)  1. A total of
12 animals per group were analysed.
Vasculature staining was performed on tibialis anterior frozen sections, blocked
for 1 h with 2% BSA in PBS; endothelial cells were detected using FITC-conjugated
lectin from Triticum vulgaris (L4895 1:200; Sigma) and vascular smooth muscle
cells using a Cy3-conjugated anti-a-SMA mouse monoclonal antibody (clone 1A4
1:200; Sigma). Nuclei were stained with DAPI (H-1,200, Vector laboratories).
Western blotting. To quantify the levels of LC3B and pAMPK/AMPK proteins
in vivo, mice hearts transduced with AAV9-control or AAV9-ghrelin were
harvested 2 days after MI, snap frozen in liquid nitrogen and stored at  80 C
before lysis in RIPA buffer (20mM Tris-HCl, pH 7.4; 150mM NaCl; 1mM EDTA;
1mM EGTA; 0.5% NaDOC; 0.5% NP-40 and 0.1% SDS) containing Protease
Inhibitor Cocktail Tablets (Roche), Phosphatase Inhibitor Cocktail (Thermo
Scientific) and 1mM phenylmethyl sulphonyl fluoride. Protein concentration was
determined by the Bradford method (Bio-Rad Laboratories). For LC3B detection,
total protein extract (50 mg) was resolved on 14% SDS–polyacrylamide gel
electrophoresis (SDS–PAGE) and transferred to polyvinylidene difluoride
membranes (GE Healthcare). Total protein extract was resolved on 8% SDS–PAGE
and transferred to nitrocellulose membranes (GE Healthcare) for pAMPK/AMPK.
Immunoblots were blocked in 5% bovine serum albumin in TBS-Tween (50mM
Tris-HCl, pH 7.4; 200mM NaCl and 0.1% Tween-20), overnight at 4 C and
incubated for 2 h at room temperature with the primary antibodies for LC3B
(L7543, 1:2,000; Sigma-Aldrich), pAMPK (2531, 1:1,000; Cell Signalling) or AMPK
(2532, 1:1,000; Cell Signalling) and then for 1 h at room temperature with the
HPR-conjugated goat anti-rabbit secondary antibody (31,460, 1:5,000; Thermo
Scientific). As a gel loading control, the membranes were incubated for 30min with
conjugated mouse monoclonal anti-b-Actin (A3854 1:25,000; Sigma-Aldrich).
Proteins were detected by enhanced chemiluminescence (GE Healthcare).
The same lysis procedure was used to obtain total protein extract from tibialis
anterior muscles of CD1 mice 7 days after peripheral ischaemia and autophagy
induction was evaluated using anti-p62 antibody (GP62-C 1:2,000; PROGEN
Biotechnik GmbH) for 2 h at room temperature and then the HPR-conjugated
goat anti-guinea pig secondary antibodies (106-035-003 1:5,000; Jackson
ImmunoResearch) for 1 h at room temperature. The level of Atg5 protein in
HL-1 cells after Atg5 genomic silencing was quantified using the rabbit monoclonal
anti-Atg5 antibody (12,994 1:2,000; Cell Signalling). Full-length uncropped images
of gels are shown in Supplementary Fig. 8.
Enzyme immunoassay analysis (EIA). Intracardiac injection of AAV vectors
(AAV9-control or AAV9-ghrelin, n¼ 4 per group; 1 1011 vg per animal) in 8- to
10-week-old female CD1 mice, was performed as described above for animals that
underwent MI. Plasma and heart tissues of the injected animals were collected
90 days after AAV injection, tissues were prepared as previously described62, and
the levels of acyl and des-acyl ghrelin peptides were assayed by specific EIA kits
from SPIBio (Bertin Pharma, France), according to the protocol provided by the
supplier.
TUNEL and caspase 3/7 assays for apoptosis detection. TUNEL assay was
performed on frozen sections of tibialis anterior muscles collected 7 days after
hindlimb ischaemia, on LV infarcted hearts, collected 2 days after MI and on
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primary neonatal rat cardiomyocytes. Both cells and tissue sections were fixed with
4% paraformaldehyde (PFA) and permeabilized with 0.5% Triton X-100 for
15min. After 1 h in blocking solution (2% BSA) at 37 C, heart tissues and primary
neonatal rat cardiomyocytes were stained with the primary antibody against
sarcomeric a-actinin (EA-53 1:200, Abcam) for 2 h. Alexa Fluor-488 donkey
anti-mouse (A-21202 1:500; Life Technology) was used as a secondary antibody.
Skeletal muscles were stained with the FITC-conjugated lectin from Triticum
vulgaris (L4895, 1:200; Sigma). Apoptotic cells were visualized by in situ cell death
detection kit, TMR red (Roche Diagnostics), according to the manufacturer’s
instructions. Nuclei were stained with DAPI (H-1200, Vector laboratories, CA).
All images were acquired by a DMLB upright fluorescence microscope (Leica
Mycrosystems) equipped with charge-coupled device camera (CoolSNAP CF,
Roper Scientific) using MetaView 4.6 quantitative analysis software (MDS
Analytical Technologies). At least five high-magnification fields were counted for
each experimental condition.
Apoptosis for rat neonatal cardiomyocytes and HL-1 cells treated with
doxorubicin (0.5 and 1 mM, respectively) was evaluated 20 h after treatment using
the Caspase-Glo 3/7 Assay System (Promega) according to the protocol provided
by the supplier.
RNA and DNA extraction and quantification. Total RNA from tissue samples
was extracted using TRIzol reagent (Invitrogen) according to the manufacturer’s
instructions, digested by DNAseI and reverse-transcribed using hexameric random
primers. Quantification of gene expression was performed by quantitative real-time
PCR using the primers and probes reported in the Supplementary Table 3. The
murine housekeeping gene GAPDH was used to normalize the results. All the
amplifications were performed using a BIORAD CFX96 real-time machine, using
pre-developed and custom-designed assays (Applied Biosystems) or SYBRGreen
(Bio-Rad Laboratories). Quantification of individual vector DNA in muscle
samples was performed by Q-PCR using SYBRGreen. A Taqman probe and
primers that specifically recognize the CMV promoter, which is common to all the
AAV vectors in the study, was used to quantify total viral genomes. Primers and
probes for viral DNA quantifications are reported in Supplementary Table 3.
Neonatal rat cardiomyocyte isolation and treatment. Ventricular myocytes
from 1- to 2-day-old Wistar rats were prepared according to a previously described
protocol, yielding 90% purity63. In details, the hearts were retrieved, the ventricles
isolated from atria and vessels and minced in small pieces down to a diameter of
B2–3mm. The fragments were dissociated in CBFHH (calcium and bicarbonate-
free Hanks with HEPES) buffer containing 2mgml 1 of trypsin and 20mgml 1
of DNase II, repeating the digestion in fresh buffer approximately ten times for
10min each with slow stirring, followed by ten times up and down gentle pipetting
of tissue pieces. After each cycle, the supernatant was collected into a solution
containing calf serum (10%, v/v) to neutralize the action of trypsin. At the end of
the cycles of digestion, the collected cells were centrifuged for 10min at 1,200 r.p.m.
and the cellular pellet was resuspended in DMEM containing 5% fetal bovine
serum (FBS). Cells were preplated for 2 h into 100-mm dishes, in order to allow the
engraftment on the plate of fibroblasts. By this procedure, stromal cells were
separated from unattached myocytes that were then plated in dishes for primary
cells. Neonatal rat ventricular myocytes were plated at low density in DMEM high
glucose containing 5% FBS, vitamin B12 (2mgml 1) and penicillin–streptomycin
(100Uml 1) and cultured as described previously64.
Cardiomyocytes were infected with AAV vectors at a MOI: 5 104 vg per cell
the day after plating; 12 h later, the culture medium was changed. After additional
12 h, cells were treated with isoproterenol hydrochloride 10 mM (Sigma) for 48 h or
doxorubicin hydrochloride 0.5 mM (Sigma) for 24 h. Viability was assessed using
the in situ cell death detection kit, TMR red (Roche) as detailed in the
Supplementary Information. After staining, cells were fixed in 4% PFA and
fluorescence was analysed by the ImageXpressMICROTM microscope and the
MetaXpress software, both from Molecular Devices.
Analysis of autophagy in cultured cells. HL-1 atrial cardiomyocyte cells65
were kindly provided by Dr William Claycomb (LSU Health Sciences Center,
Louisuana) and were cultured on gelatin/fibronectin-coated plates in Claycomb
medium (Sigma Aldrich) supplemented with 10% FBS, penicillin–streptomycin
(100Uml 1), norepinephrine 0.1mM and L-glutamine 2mM. For endogenous
autophagy analysis, cells were seeded in four-chamber slides (6 104 cells per well)
and, after 24 h, treated with murine acyl or des-acyl ghrelin 1 mM (Bachem), for 4 h.
To analyse autophagic flux, cells were treated with the peptides in the presence
of the lysosomotropic alkalinizing agent chloroquine (Sigma-Aldrich) at a
concentration of 10 mM, to inhibit autophagosome-lysosome fusion66.
As autophagy inhibitor wortmannin (Sigma-Aldrich) 0.5 mM was used. After 4 h,
cells were fixed with 4% PFA at room temperature and permeabilized with 0.1%
Triton X-100 for 5min. After 1 h in blocking solution (5% BSA), cells were
incubated with the primary rabbit anti-LC3B antibody (L7543, 1:200;
Sigma-Aldrich) for 2 h. Alexa Fluor 488 donkey anti-mouse (A-21202, 1:500;
Life Technology) was used as secondary antibody. Cells were imaged at  100
magnification using a Zeiss LSM-510 confocal laser-scanning microscope.
The percentage of cells showing numerous LC3 puncta (430 dots per cell)67 was
quantified using the cell counter tool of the ImageJ software (NIH). A minimum of
30 cells were scored for each condition.
C2C12 myogenic cells (ATCC CRL-1772) were cultured in high-glucose
DMEM plus 10% FBS and penicillin–streptomycin (100Uml 1) and treated for
4 h with murine acyl or des-acyl ghrelin (1mM) in the presence or absence of
chloroquine (10 mM) to evaluate LC3I/II conversion by western blot.
To analyse autophagic flux in vitro neonatal rat cardiomyocytes, HL-1 and
C2C12 cells were plated in four-chamber slides (1 105, 6 104 and 2 104 cells
per well, respectively) and transfected with ptfLC3 using Lipofectamine 2,000 (Life
Technologies) according to the manufacturer’s instructions. PtfLC3 was a gift from
Tamotsu Yoshimori (Addgene plasmid # 21074). Twenty-four hours after
transfection, culture medium was replaced by fresh medium and after additional
24 h cells were treated with acyl or des-acyl ghrelin, either in complete or in
starvation medium (DMEM without glucose, sodium pyruvate and FBS). Four
hours later, cells were fixed with 4% PFA and imaged at  100 magnification using
a Zeiss LSM-510 confocal laser-scanning microscope. LC3 green and red dots were
quantified using the cell counter tool of the ImageJ software. A minimum of
30 cells were scored for each condition.
SiRNA knockdown of Atg5 was performed on HL-1 cells seeded in Primaria
96-well plates (BD Falcon) and transfected at a final concentration of 50 nM with
mouse Atg5 siRNA (M-064838-02-0005; Dharmacon) by a standard reverse
transfection61 using Lipofectamine RNAiMAX (Life Technologies). Twenty-four
hours after transfection, culture medium was replaced by fresh medium and after
additional 24 h cells were treated with murine acyl or des-acyl ghrelin (1 mM) and
doxorubicin (1mM). Twenty hours later apoptosis, activation was measured using
the Caspase-Glo 3/7 Assay System (Promega).
Autophagic flux analysis in vivo. To assess induction of autophagy in vivo, we
generated an AAV9 vector expressing the mRFP-EGFP tandem fluorescent-tagged
LC3, derived from the ptfLC3 plasmid24, under the control of CMV promoter.
After MI, this vector was administered together with AAV9-control or
AAV9-ghrelin (final titer of 1 1011 vg per animal) into the infarct border zone of
3-month-old female CD1 mice (n¼ 6). Animals were killed 7 days later and EGFP
and mRFP signals were analysed on frozen sections by confocal microscopy.
The tissues were imaged at  63 magnification using a Zeiss LSM-510 confocal
laser-scanning microscope; LC3 green and red dots were quantified using the
ImageJ software, as described in the previous paragraph.
Fluorescence microscopy for mitochondria. To evaluate the formation of
autophagic vesicles including mitochondria, HL-1 cells (6 104 cells per well) were
cultured in four-chamber slides in complete Claycomb medium. After 24 h, cells
were starved as described above, treated with 1 mM acyl or des-acyl ghrelin for 4 h
with or without chloroquine and then loaded with 500 nM MitoTracker Orange
CMTMRos (Life Technologies) at 37 C for 30min. Cells were washed with PBS,
fixed with 4% PFA and then incubated with the anti-LC3B antibody (L7543, 1:200;
Sigma-Aldrich) for 2 h. Alexa Fluor 488 anti-rabbit was used as secondary
antibody. Cells were imaged at  100 magnification using a confocal
laser-scanning microscope.
Transmission electron microscopy. HL-1 cells pellets were fixed in 2%
glutaraldehyde (Electron Microscopy Sciences) containing 5mM CaCl2 in 0.1M
cacodylate buffer, pH 7.3, for 1 h at room temperature, rinsed twice for 10min with
the buffer and fixed with 1% osmium tetroxide and 0.8% potassium ferricyanide in
the same buffer for 1 h at 4 C. Pellets were dehydrated in ascending alcohols,
treated with propylene oxide and embedded in Araldite (Electron Microscopy
Sciences). Ultrathin sections of the samples were cut on a Top Ultra 150
ultramicrotome (Pabish) and collected on 300-mesh copper grids. The grids were
stained with uranyl acetate and lead citrate and examined at 80 kV using a Jeol
100S transmission electron microscopy.
Mitochondrial H2O2 production. ROS production in intact isolated mitochondria
was assessed by quantification of H2O2 synthesis using the Amplex Red-horse-
radish peroxidase method68 as previously described69. Neonatal rat cardiomyocytes
were plated in 100mm2 plates (3 106 cells); after 2 days, they were starved and
treated with acyl or des-acyl ghrelin (1 mM) for 48 h. Cells were then collected and
processed by homogenization in Sucrose-Hepes-EGTA (SHE) buffer
(260mmol l 1 sucrose, 1mmol l 1 EGTA, 10.5mmol l 1 HEPES, pH¼ 7.2) in
ice. Mitochondria were then isolated by differential centrifugation: nuclei and
myofibrillar fraction were removed (720g, 4 C, 5min), and mitochondria
centrifuged (10,000g, 4 C, 5min), washed in buffer SHE and resuspended in
Respiration buffer (4mmol l 1 KH2PO4, 1mmol l 1 MgCl2, 14mmol l 1 NaCl,
125mmol l 1 KCl, 20 mmol l 1 EGTA, 20mmol l 1 HEPES, pH¼ 7.4).
Mitochondrial suspension was added to a 96-well microplate containing in each
well 10 volumes assay buffer 10 mmol l 1 Amplex Red (Invitrogen), 0.4Uml 1
horseradish peroxidase, 0.2% BSA in buffer R and 1 volume of ultrapure H2O,
diluted respiration uncoupler (CCCP) or inhibitor (AA). After an incubation of
20min at 37 C and the addition of either ultrapure H2O or respiration substrate,
state 4 mitochondrial respiration H2O2 production was measured monitoring the
conversion of Amplex Red to resorufin using a microplate fluorimeter (Infinite
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F200, Tecan Group). Working dilutions of respiratory inhibitors and substrates
were prepared immediately before use. The final concentrations in the assay were:
8mmol l 1 glutamate, 4mmol l 1 malate; 10mmol l 1 succinate (S);
50mmol l 1 palmitoyl-L-carnitine, 2mmol l 1 malate. The rate of H2O2 synthesis
was calculated by interpolation of resorufin fluorescence variation over time with a
calibration curve from H2O2 standards. Data were normalized for sample
mitochondrial content as measured by classic citrate synthase activity assay and
expressed as nmol UCS 1min 1.
Statistical analysis. All data are presented as mean±standard error of the mean
(s.e.m.). One-way analysis of variance and Bonferroni post-hoc test were used to
compare multiple groups. In the case of experiments entailing the follow-up of the
same animals over multiple time points, we used analysis of variance on repeated
measures to analyse statistical significance of the differences between groups over
time. Pairwise comparison between groups was performed using the Student’s
t-test. The Kolmogorov–Smirnov test was used to compare continuous
distributions. Po0.05 or lower was considered statistically significant. Statistical
analysis was carried out using Prism Software (GraphPad).
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